Back to Careers
InVivo spotlights CEO and Co-Founder Dr. Hanadie Yousef’s Journey with Juvena Therapeutics
Back to Careers
Jeanne Jew, MBA
Former CBO ALX Oncology
Former SVP BD, Paratek, KaloBios
Former VP BD, Onyx
Former Board member: Catalyst Biosciences
MBA, Cornell
Learn more about Jeanne
LinkedIn
Back to Careers
Jeremy O’Connell presents video discussing JUV-161 for myotonic dystrophy type 1 (DM1)
Back to Careers
Juvena CEO and CO-Founder Dr. Hanadie Yousef featured in San Francisco Business Times article highlighting women biotech leaders
Back to Careers
Ashil Koranne presented a poster at the 2024 MDA Clinical & Scientific Conference highlighting Juvena Therapeutics’ promising preclinical development of JUV-161, a novel fusion protein for treating Myotonic Dystrophy Type 1.
Back to Careers
Juvena recognized by The Wall Street Journal for developing regenerative therapies aimed at weight loss and prevention of muscle wasting
Back to Careers
Juvena gets FDA Orphan Drug nod for muscle regeneration therapy
Back to Careers
Juvena’s JUV-161 named FDA orphan drug for DM1
Back to Careers
Juvena’s JUV-161 awarded US orphan drug designation for myotonic dystrophy type 1
Back to Careers
Juvena Therapeutics is recognized in Biospace’s Top 30 list, “NextGen Class of 2024: Top Life Sciences Startups to Watch This Year”
